TKNO
NASDAQAlpha Teknova Inc.
$7.33-0.75 (-9.34%)
Alpha Teknova Inc. (TKNO) is a Biotechnology: In Vitro & In Vivo Diagnostic Substances company listed on NASDAQ. In the last 30 days Quantisnow tracked 8 wire items for TKNO, including 3 offerings, 3 SEC filings and 1 press release or news item. The most recent was published Oct 21, 2026.
Price$7.33-0.75 (-9.34%)
01:30 PM07:45 PM
News · 26 weeks25+133%
2026-05-032026-10-25
Mix1690d
- SEC Filings5(31%)
- Analyst3(19%)
- Other3(19%)
- Offering3(19%)
- Earnings2(13%)
Latest news
25 items- PRTeknova to Report Third Quarter 2026 Financial Results on November 4, 2026HOLLISTER, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2026, on Wednesday, November 4, 2026, following the close of market. Teknova will host a webcast and conference call on Wednesday, November 4, 2026, beginning at 6:00 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you wo
- SECSEC Form 8-K filed by Alpha Teknova Inc.8-K - Alpha Teknova, Inc. (0001850902) (Filer)
- SECSEC Form 424B5 filed by Alpha Teknova Inc.424B5 - Alpha Teknova, Inc. (0001850902) (Filer)
- PRTeknova Announces Pricing of $40 Million Public Offering of Common StockHOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the pricing of its underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $5.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $40 million. Teknova has also granted the underwriters a 30-day option to purchase up to 1,200,000 additional shares of its common stock. All of the shares of com
- SECSEC Form 424B5 filed by Alpha Teknova Inc.424B5 - Alpha Teknova, Inc. (0001850902) (Filer)
- PRTeknova Announces Proposed Public Offering of Common StockHOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that it has commenced an underwritten public offering of its common stock. Teknova also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of shares of its common stock offered in the offering. All of the shares of common stock to be sold in the proposed offering are to be sold by Teknova. The proposed offering is subject to market and other conditions, and there can be no as
- PRTeknova Announces Preliminary Third Quarter Financial ResultsHOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced in conjunction with its filing of a preliminary prospectus supplement, preliminary unaudited financial results for the three months ended September 30, 2026. Set forth below are certain preliminary unaudited financial results for the three months ended September 30, 2026 and as of September 30, 2026: Revenue for the three months ended September 30, 2026 is estimated to be within the range of $12.5 million and $12.7 million.Gr
- PRTeknova and Pluristyx Announce FDA Drug Master File for the PluriFreeze™ Cryopreservation SystemHOLLISTER, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), and Pluristyx, Inc. ("Pluristyx"), today announced that Pluristyx is completing a Type II Drug Master File (DMF) for the PluriFreeze™ cryopreservation system for submission to the U.S. Food and Drug Administration (FDA). The DMF will support drug makers seeking to incorporate PluriFreeze into their clinical development and manufacturing programs. Teknova is a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, and is the exclusive manufacturer and distributor of PluriFreeze in the United States a
- ANALYSTJefferies initiated coverage on Alpha Teknova with a new price targetJefferies initiated coverage of Alpha Teknova with a rating of Buy and set a new price target of $9.00
- PRTeknova Expands Custom Manufacturing with Fill-Tek™ Dispensing System for Flexible Single-Use Bag FillingHOLLISTER, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today introduced the Fill-Tek™ Dispensing System. Fill-Tek is a proprietary single-use bag dispensing capability that fills an entire custom reagent order across multiple bag sizes and quantities as a single lot. The Fill-Tek system removes the per-bag-size minimums that come with fixed manifold designs, so manufacturers can order the formats their process calls for rather than the formats the fill line requires. "Your process is one of a ki
- ANALYSTAlpha Teknova upgraded by BTIG Research with a new price targetBTIG Research upgraded Alpha Teknova from Neutral to Buy and set a new price target of $8.00
- SECSEC Form 10-Q filed by Alpha Teknova Inc.10-Q - Alpha Teknova, Inc. (0001850902) (Filer)
- SECAlpha Teknova Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Alpha Teknova, Inc. (0001850902) (Filer)
- PRTeknova Reports Second Quarter 2026 Financial ResultsSecond quarter 2026 total revenue was $12.2 million, up 18% over the same quarter prior yearCompany raises 2026 revenue guidance to $45-47 millionLaunched proprietary AI-powered Build-Tek™ custom order configurator, giving developers a faster path from preclinical to clinical manufacturing HOLLISTER, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2026. "We delivered more than $12 million in quarterly revenue fo
- PRTeknova Launches Build-Tek™, a Proprietary AI Reagent Assistant That Allows Customers to Configure Complex Custom Product Requests in MinutesHOLLISTER, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today launched Build-Tek™, an AI-powered custom order configurator that enables developers of therapies and diagnostics to design complex custom products and submit a request for quote in minutes. Build-Tek expands on the original buffer configurator Teknova introduced in 2024, extending custom configuration functionality across the Company’s full range of products, container formats, and manufacturing grades through a highly interactive self-
- ANALYSTRoth Capital initiated coverage on Alpha Teknova with a new price targetRoth Capital initiated coverage of Alpha Teknova with a rating of Buy and set a new price target of $7.00
- PRTeknova to Report Second Quarter 2026 Financial Results on August 5, 2026HOLLISTER, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, following the close of market. Teknova will host a webcast and conference call on Wednesday, August 5, 2026, beginning at 6:00 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like
- INSIDERDirector Demski Martha J disposed of 12,000 shares and acquired 12,000 shares, closing all direct ownership in the company (SEC Form 4)4 - Alpha Teknova, Inc. (0001850902) (Issuer)
- INSIDERSEC Form 4 filed by Director Vos Alexander4 - Alpha Teknova, Inc. (0001850902) (Issuer)
- INSIDERSEC Form 4 filed by Director Robertson Brett4 - Alpha Teknova, Inc. (0001850902) (Issuer)
- INSIDERSEC Form 4 filed by Director Demski Martha J4 - Alpha Teknova, Inc. (0001850902) (Issuer)
- SECAlpha Teknova Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Alpha Teknova, Inc. (0001850902) (Filer)
- SECSEC Form 10-Q filed by Alpha Teknova Inc.10-Q - Alpha Teknova, Inc. (0001850902) (Filer)
- SECAlpha Teknova Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics8-K - Alpha Teknova, Inc. (0001850902) (Filer)
- PRTeknova Reports First Quarter 2026 Financial ResultsFirst quarter 2026 total revenue was $11.1 million, up 13% over the same quarter prior yearCompany reaffirms 2026 revenue guidance of $42-44 million HOLLISTER, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the first quarter ended March 31, 2026. "We had a great start to 2026," said Stephen Gunstream, President and Chief Executive Officer at Teknova. "The substantial investments we've made since 2021, combined with an improved market backdrop, p
TKNO FAQ
7 questionsWhat is the latest news on TKNO?
In the last 30 days Quantisnow tracked 8 wire items for TKNO: 3 offerings, 3 SEC filings, 1 press release or news item and 1 earnings update. The most recent was published on October 21, 2026.Where does TKNO stock trade?
Alpha Teknova Inc. (TKNO) is listed on NASDAQ.What sector and industry is TKNO in?
Alpha Teknova Inc. operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.When did Alpha Teknova Inc. go public?
Alpha Teknova Inc. (TKNO) completed its IPO in 2021.What are analysts saying about TKNO?
Alpha Teknova Inc. has had 8 recent analyst actions on file. The most recent action was from Jefferies: Buy with a $900.00 price target on 2026-09-17. Recent price targets range from $700.00 to $2700.00.What companies are similar to TKNO?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), LNTH (Lantheus Holdings Inc.), ORKA (Oruka Therapeutics Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), NEOG (Neogen Corporation). Compare TKNO side-by-side with any of them on Quantisnow.How can I track TKNO on Quantisnow?
Quantisnow aggregates Alpha Teknova Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TKNO to receive live email and push alerts on every new disclosure.